NASDAQ$BNGO
BioNano Genomics Inc · Q1 2025 earnings
Q1 2025 earnings · · After market close · Investor relations
Briefing
BioNano reported a decline in revenue and narrowed net loss in Q1 2025 amid a strategic shift and improved gross margin.
BioNano Genomics delivered Q1 2025 revenue of $6.5 million, down 26% year-over-year, primarily due to reduced instrument and discontinued clinical services sales. Despite this, the company improved its gross margin to 46% and significantly reduced its operating expenses, resulting in a narrowed net loss.
- Revenue declined to $6.5 million from $8.8 million in Q1 2024, driven by discontinued services and lower instrument sales.
- Gross margin improved to 46%, up from 32% in the prior year quarter.
- Net loss narrowed to $3.1 million, significantly better than the $31.4 million loss in Q1 2024.
- Saphyr installed base grew 9% year-over-year to 379 systems.
Headline financials
Revenue & EPS history
BioNano · Revenue · Quarterly
$6.46M
Revenue by segment
BioNano · $9.32M total across 2 segments · Q3 2023
- Product Revenue$6.46M+79.0%69.3%
- Service and Other Revenue$2.86M-20.8%30.7%
Forward guidance
BioNano expects full-year 2025 revenue to range from $26.0M to $30.0M and plans to install 15–20 new OGM systems during the year.
Tailwinds
- Full-year 2025 revenue guidance reaffirmed at $26.0M to $30.0M.
- Q2 2025 revenue projected between $6.3M and $6.8M.
- Cost savings have extended cash runway into Q1 2026.
- Operational efficiency and restructuring have significantly lowered expenses.
- Continued global adoption of OGM and strong publication support.
Headwinds
- Revenue fell 26% year-over-year due to discontinued services and reduced instrument sales.
- Instrument sales decreased to $0.7 million from $1.6 million in Q1 2024.
- Clinical services now contribute no revenue post-discontinuation.
- Consumable sales growth limited to existing base after adjusting for new customers.
- Continued net losses highlight need for further revenue growth or funding.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q1 2025
-3.3%
Avg return
Earnings day
-5.4%
Avg return
5 days after
-7.7%
Avg return
30 days after
40%
12 / 30 earnings
Positive
+15.5%
Q4 2018
Best reaction
-29.8%
Q4 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | +0.9% | +1.6% | — | |
| Q1 2026 | -0.8% | -9.5% | -7.9% | |
| Q3 2025 | +2.8% | +4.8% | +10.2% | |
| Q1 2025 | +2.9% | +0.8% | -2.4% | |
| Q4 2024 | +11.1% | +8.6% | +43.4% | |
| Q3 2024 | -3.4% | -11.5% | -7.7% | |
| Q2 2024 | -21.5% | -23.5% | -13.7% | |
| Q1 2024 | +2.7% | +7.3% | -9.4% | |
| Q4 2023 | +0.0% | -5.8% | -18.2% | |
| Q3 2023 | -7.0% | -10.5% | +2.8% | |
| Q2 2023 | -0.2% | -13.9% | -15.7% | |
| Q1 2023 | +6.9% | -9.6% | +0.0% | |
| Q4 2022 | -8.4% | -5.3% | -19.8% | |
| Q3 2022 | +2.7% | +2.2% | -6.3% | |
| Q2 2022 | +6.6% | +0.0% | +2.2% | |
| Q1 2022 | -16.1% | -24.2% | -10.8% | |
| Q4 2021 | +1.4% | -10.7% | +20.6% | |
| Q3 2021 | -9.8% | -13.7% | -44.4% | |
| Q2 2021 | +5.4% | +4.4% | -1.0% | |
| Q1 2021 | +13.9% | +22.8% | +59.9% | |
| Q4 2020 | -17.9% | -14.4% | -34.1% | |
| Q3 2020 | -7.4% | -5.4% | -10.7% | |
| Q2 2020 | -8.4% | -6.5% | -32.5% | |
| Q1 2020 | -8.4% | -11.8% | +21.6% | |
| Q4 2019 | -29.8% | -30.3% | -74.3% | |
| Q3 2019 | -2.1% | +17.8% | +24.4% | |
| Q2 2019 | -14.4% | -11.3% | -50.5% | |
| Q1 2019 | -11.3% | -17.0% | -28.1% | |
| Q4 2018 | +15.5% | +7.4% | -8.1% | |
| Q3 2018 | -6.0% | -5.7% | -11.9% | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro